Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Novo Nordisk files annual report with the SEC

globenewswire.com
NVO The article is a factual announcement about Novo Nordisk filing its annual report with the SEC. It does not contain any information that suggests a positive or negative outlook on the company's stock performance.

Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2025. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com.

Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial statements free of charge upon request to investor-relations@novonordisk.com.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information:

Attachment